FTSE 100 movers: AstraZeneca hit by falling revenue
31st Jan 2013 15:48
Pharmaceutical titan AstraZeneca dropped after reporting that full-year revenue fell 15 per cent due to a loss of exclusivity on several brands. The company also said that it would not buy back any shares in 2013 "in order to maintain the flexibility to invest the business". Oil giant Royal Dutch
Read moreSector movers: Pharmaceuticals under the weather as AstraZeneca takes a hit
31st Jan 2013 15:04
The pharmaceuticals and biotechnology sector was at the bottom of the pile on Thursday after a disappointing set of full-year results from AstraZeneca weighed on share prices. The company, which manufactures drugs to treat range of cardiovascular conditions, reported a 15% fall in revenue at consta
Read moreBroker tips: AstraZeneca, Diageo, Shell
31st Jan 2013 11:40
Panmure Gordon has kept its 'hold' rating and 3,000p target price for pharmaceuticals giant AstraZeneca after the firm's final results, saying that figures were not as bad as they could have been. "Overall Q4 2012 results were more resilient than expected, continuing the trend seen across the secto
Read moreLondon midday: AstraZeneca, Shell provide a drag on the Footsie
31st Jan 2013 11:36
A host of FTSE 100 heavyweights disappointed with earnings reports on Thursday morning, as market sentiment was still fragile after yesterday's shock economic contraction in the States. The world's largest economy shrank by 0.1% in the last three months of last year, a stark contrast to the 3.1% gr
Read moreBroker snap: Astra's results could have been worse, says Panmure Gordon
31st Jan 2013 09:16
Panmure Gordon has kept its 'hold' rating and 3,000p target price for pharmaceuticals giant AstraZeneca after the firm's final results, saying that figures were not as bad as they could have been. "Overall Q4 2012 results were more resilient than expected, continuing the trend seen across the secto
Read moreLondon open: FTSE 100 slips on mixed corporate earnings
31st Jan 2013 08:18
The FTSE 100 slumped in early trading on Thursday with heavyweight stocks AstraZeneca, Diageo, Shell and Vedanta providing a drag after disappointing the market with results. Stocks were also tracking US and Asian markets lower after yesterday's news that the US contracted in the fourth quarter of
Read more2012 revenue down 15 per cent at AstraZeneca
31st Jan 2013 07:04
Revenue fell 15 per cent in 2012 at biopharmaceuticals company AstraZeneca, according to an update published by the FTSE 100 company on Thursday morning. The company, which manufactures drugs to treat range of cardiovascular conditions, stated that the reduction in revenue reflected a loss of exclu
Read moreThursday preview: Barrage of FTSE 100 companies unveils results
30th Jan 2013 15:53
FTSE 100 companies are set to storm Thursday with a wave of financial results. UK pharmaceutical giant AstraZeneca will unveil its full-year statements. The drug company is expected to show a slump in revenues due to patent expirations. However, investors will be keen to hear what Astra's new Chi
Read moreTuesday broker round-up UPDATE
29th Jan 2013 07:26
Anglo American: JP Morgan takes price target from 1630p to 1680p, while its underweight rating remains unchanged. ARM Holdings: Jefferies raises target price from 693p to 805p keeping a hold recommendation. Astra Zaneca: Barclays ups target price from 3100p to 3200p and retains an equal-weight rat
Read moreSunday share tips: Tullow Oil, AstraZeneca, Aviva
27th Jan 2013 17:20
It may be time for Aidan Heavey to step aside at Tullow Oil. The former accountant, 59, is rightly feted as one of the oil industry's great entrepreneurs. Beginning with a tiny start-up in 1986 the Irishman turned Tullow into one of the most successful explorers in the world. Its 10.7bn pound market
Read moreSunday newspaper round-up: Barclays, Carney, BP
27th Jan 2013 16:23
Barclays is planning a swoop on the financial markets to raise billions of pounds of new capital ahead of a showdown with the Bank of England. Sources close to the bank say it could launch the move within weeks to kill off questions about its financial strength. All Britain's banks are on edge as th
Read moreTuesday newspaper round-up: AstraZeneca, Japan, Carpetright...
22nd Jan 2013 06:56
Health insurers and doctors in the United States are turning up their noses at AstraZeneca's much-vaunted new heart drug, according to a leading broker. Analysts at Société Générale forecast yesterday that sales of Brilinta would reach only 304 million dollars by 2015 ? barely a third of the market'
Read moreMonday broker round-up UPDATE
21st Jan 2013 07:02
Abbey Protection: Numis increases target price from 90p to 120p and upgrades to add. Admiral: Goldman Sachs upgrades to buy from neutral, raising its price target to 1500p from 1160p before. Aggreko: Bank of America lowers target price from 2700p to 1950p and downgrades to neutral. Anglo Americ
Read moreSunday newspaper round-up: RBS, HMV, Japan
20th Jan 2013 16:31
Top managers at the RBS investment bank, including its Chief Executive, John Hourican, who it has since emerged was planning to leave after reshaping the business - may quit to take responsibility for the disregard shown for the market even though they are not personally culpable. While the evidence
Read moreWednesday newspaper round-up: AstraZeneca, Facebook, PPI claims...
16th Jan 2013 06:54
The new boss of AstraZeneca has dismissed two of the drugs company's leadership team as part of a shake-up intended to tackle flagging sales and scientific setbacks. The head of research and development, Martin Mackay, and its global commercial chief, Tony Zook, are to leave the pharmaceuticals grou
Read more